FDA warns neonatal device company NeoChild
The US Food and Drug Administration (FDA) has issued a warning letter to NeoChild for alleged misbranding of its neonatal devices and procedural errors.
The US Food and Drug Administration (FDA) has issued a warning letter to NeoChild for alleged misbranding of its neonatal devices and procedural errors.
The FDA stated that the firm marketed its SafeChild System's enteral feeding tubes and extension sets before filing a premarket approval or getting 510(k) clearance. In addition, the July 29 letter stated that the silicone and polyurethane enteral feeding tubes and the PVC extension sets were not approved for an investigational device exemption.
NeoChild is to submit a premarket approval so the FDA can evaluate the information and decide whether the products may be marketed legally.
In addition, the FDA also cited NeoChild for failure to develop or implement written medical device report procedures from the time it started distributing devices in March 2007 to the date of an April inspection.
Major congenital malformations not linked to first trimester tetracycline use
November 22nd 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Higher pregnancy risks associated with maternal hidradenitis suppurativa
November 8th 2024A study of over 1 million births in Quebec reveals that pregnant women with hidradenitis suppurativa face increased risks of pregnancy complications and long-term health issues for both themselves and their offspring.
